Quarterly report · Q1
9987.TEDINET S100RMWL
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥573.6bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥553.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥3.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥5.0bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.1bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.3bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.3bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥1.19T | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥772.0bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥418.1bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥419.3bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥114.2bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥40.4 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.49 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥23.9bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥23.9bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3m |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥38m |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥12.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥9.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥521m |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥63.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥7.1bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥56.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥213m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥553.4bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥539.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥13.7bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥653.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥573.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥80.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥24.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥24.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥198m |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥11.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.2bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥8.6bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥613m |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥49.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥42.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥242m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥533.5bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥519.6bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥618.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥553.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥65.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥3.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 344
| Item | Context | Value | Unit |
|---|---|---|---|
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 6223000000 | JPY |
| Revaluation reserve for land net of tax oci | Prior1YTDDuration | － | JPY |
| Revaluation reserve for land net of tax oci | CurrentYTDDuration | -44000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YTDDuration | 18000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYTDDuration | -0 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | -136000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -50000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | Prior1YTDDuration | 500000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | CurrentYTDDuration | -1000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 1725000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 6126000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 4400000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 9461000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 4407000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 9469000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | -6000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | -7000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 519633000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 3154000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 24022000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 6943000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 553754000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 13820000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 8628000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 42721000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 65171000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 533454000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 11783000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 24022000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 49665000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 618925000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 2413000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 613000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 198000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 242000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3468000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 539754000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 2942000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 23871000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 7075000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 573644000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 13685000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 9856000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 56723000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 80269000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 553440000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 12799000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 23875000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |